PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Immodulon Therapeutics Limited

USPTO PatentsView assignee record - 11 granted patents across 5 technology areas, active 2018–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Explore the portfolio See the ranking
11
Total patents granted
5
CPC technology areas
15.0
Avg claims per patent
+900%
5-year filing velocity

The verdict

Immodulon holds 11 US patents across 5 technology areas, rank #24,508 of 50,000 tracked assignees.

#24,508
of 50,000 US assignees by volume
Top 73%
by Innovation Score (28.4/100)
15.0
avg claims per patent
+900%
filing velocity, last 5 yrs

Portfolio overview

Immodulon Therapeutics Limited has been granted 11 US utility patents between 2018 and 2024, placing Immodulon Therapeutics Limited at rank #24,508 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.0 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Immodulon Therapeutics Limited is one of the more focused assignees in the PatentsView dataset. By volume, Immodulon sits between ID Technology Llc (11 patents, rank #24,504) and Indian Institute OF Technology Guwahati (11 patents, rank #24,512) - the closest US assignees by grant volume. The composite Innovation Score of 28.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 10 grants, compared with 1 in the 2015–2019 window, a +900% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Immodulon Therapeutics Limited's 15.0 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Immodulon Therapeutics Limited against peers pursuing similar technology classes.

Who files at Immodulon's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Immodulon holds 11 patents at rank #24,508, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Immodulon's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

28 Top 73% higher than 27% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). This entry sits in this band. 30–40: 15,294 US assignees (31%). Above this entry. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

012345 201820202021202220232024 1
USPTO utility patent grants by year · 2018–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table
Immodulon Therapeutics Limited patent grants by year, 2015–2025
Year Patents Granted Share of Period
2018 1 9.1%
2020 3 27.3%
2021 4 36.4%
2022 1 9.1%
2023 1 9.1%
2024 1 9.1%

Which technologies does Immodulon Therapeutics Limited patent most?

Top 5 of 5 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Accelerating

Where it ranks

Overall rank by patents

#24,508

Across all tracked assignees

Innovation Score

28.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Immodulon Therapeutics Limited hold?
Immodulon Therapeutics Limited holds 11 US granted patents filed between 2018 and 2024, spanning 5 technology areas.
What is Immodulon Therapeutics Limited's Innovation Score?
Immodulon Therapeutics Limited has an Innovation Score of 28.4 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Immodulon Therapeutics Limited focus on?
Immodulon Therapeutics Limited's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 11 patents. The company has filed patents in 5 CPC subclasses total.
Is Immodulon Therapeutics Limited's patent filing rate increasing or decreasing?
Immodulon Therapeutics Limited's recent filing velocity is +900% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Immodulon Therapeutics Limited's patents?
Immodulon Therapeutics Limited's patents average 15.0 claims each. This falls within the standard range, providing solid legal coverage.
How is the Immodulon Therapeutics Limited patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Immodulon's 11 grants land it in the top 73% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Immodulon ranks #24,508 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.